Literature DB >> 23043317

RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification.

Lonneke Haer-Wigman1, Barbera Veldhuisen, Remco Jonkers, Martin Lodén, Tracey E Madgett, Neil D Avent, Masja de Haas, C Ellen van der Schoot.   

Abstract

BACKGROUND: The presence of a D variant may hamper correct serologic D typing, which may result in D immunization. D variants can be determined via RHD genotyping. However, a convenient single assay to identify D variants is still lacking. We developed and evaluated a multiplex ligation-dependent probe amplification (MLPA) assay to determine clinically relevant RHD and RHCE variant alleles and RHD zygosity. STUDY DESIGN AND METHODS: We analyzed 236 cases (73 normal and 163 selected samples) with the RH-MLPA assay, which is able to determine 79 RHD and 17 RHCE variant alleles and RHD zygosity. To confirm the results, mutations were verified by RHD and/or RHCE exon-specific sequencing and RHD zygosity was verified by quantitative real-time polymerase chain reaction (PCR) for 18 cases.
RESULTS: In 99% of the cases, the RH-MLPA assay correctly determined whether a person carried only wild-type RHD and RHCE alleles (n = 69) or (a) variant RHD allele(s) and/or (a) variant RHCE allele(s) (n = 164). In only three cases, including two new RHD variant alleles, the variant allele was not identified, due to lack of detecting probes. These were RHD*DCS2, a new partial RHD allele, RHD*525T (Phe175Leu), and a new D- null allele, RHD*443G (Thr148Arg). All RHD (n = 175) and RHCE variant alleles (n = 79) indicated by the RH-MLPA assay were confirmed by sequencing. RHD zygosity was confirmed by quantitative PCR. Two hematopoietic chimeras were recognized.
CONCLUSION: The RH-MLPA genotyping assay is a fast, easy, and reliable method to determine almost all clinically relevant RHD and RHCE variant alleles, RHD zygosity, and RHD+/RHD- chimeras in blood donors, blood recipients, and pregnant women.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23043317     DOI: 10.1111/j.1537-2995.2012.03919.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  [Genotyping of RhD-negative blood samples diagnosed by serological tests from patients waiting for kidney transplantation].

Authors:  Shao-Jie Fu; Yan-Lin Feng; Li-Xin Yu; Yun Miao; Min Luo; Yi-Bin Wang; Yi-Chen Li; Shu-Han Chen; Lu-Lu Xiao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-06-20

2.  RHD and RHCE molecular analysis in weak D blood donors and in patients with Rh antibodies against their own corresponding Rh antigen.

Authors:  Thamy C Souza Silva; Bruno R Cruz; Sidneia S Costa; Akemi K Chiba; Melca M O Barros; Dante M Langhi; José O Bordin
Journal:  Blood Transfus       Date:  2020-07       Impact factor: 3.443

3.  High-throughput method for the hybridisation-based targeted enrichment of long genomic fragments for PacBio third-generation sequencing.

Authors:  Tim Alexander Steiert; Janina Fuß; Simonas Juzenas; Michael Wittig; Marc Patrick Hoeppner; Melanie Vollstedt; Greta Varkalaite; Hesham ElAbd; Christian Brockmann; Siegfried Görg; Christoph Gassner; Michael Forster; Andre Franke
Journal:  NAR Genom Bioinform       Date:  2022-07-13

4.  Comprehensive Molecular Analysis of Serologically D-Negative and Weak/Partial D Phenotype in Thai Blood Donors.

Authors:  Jairak Thongbut; Loann Raud; Claude Férec; Charuporn Promwong; Pornlada Nuchnoi; Yann Fichou
Journal:  Transfus Med Hemother       Date:  2019-04-03       Impact factor: 3.747

5.  Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands.

Authors:  Masja de Haas; Florentine F Thurik; Catharina P B van der Ploeg; Barbera Veldhuisen; Hoang Hirschberg; Aicha Ait Soussan; Heleen Woortmeijer; Frithjofna Abbink; Godelieve C M L Page-Christiaens; Peter G Scheffer; C Ellen van der Schoot
Journal:  BMJ       Date:  2016-11-07

6.  The Significance of RHD Genotyping and Characteristic Analysis in Chinese RhD Variant Individuals.

Authors:  Yanling Ying; Jingjing Zhang; Xiaozhen Hong; Xianguo Xu; Ji He; Faming Zhu
Journal:  Front Immunol       Date:  2021-11-12       Impact factor: 7.561

7.  RHD Genotyping of Rh-Negative and Weak D Phenotype among Blood Donors in Southeast Iran.

Authors:  Younes Sadeghi-Bojd; Naser Amirizadeh; Arezoo Oodi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-10-01

8.  Prevalence of RhD status and clinical application of non-invasive prenatal determination of fetal RHD in maternal plasma: a 5 year experience in Cyprus.

Authors:  Thessalia Papasavva; Pete Martin; Tobias J Legler; Marios Liasides; George Anastasiou; Agathoklis Christofides; Tasos Christodoulou; Sotos Demetriou; Prokopis Kerimis; Charis Kontos; George Leontiades; Demetris Papapetrou; Telis Patroclos; Marios Phylaktou; Nikos Zottis; Eleni Karitzie; Eleni Pavlou; Petros Kountouris; Barbera Veldhuisen; Ellen van der Schoot; Marina Kleanthous
Journal:  BMC Res Notes       Date:  2016-04-01

9.  Application of Multiplex Ligation-Dependent Probe Amplification Assay for Genotyping Major Blood Group Systems Including DEL Variants in the D-Negative Korean Population.

Authors:  Banseok Kim; Seung Tae Lee; Sinyoung Kim; Jong Rak Choi; Hyun Ok Kim
Journal:  Ann Lab Med       Date:  2018-01       Impact factor: 3.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.